Phase 1/2, open-label, first-in-human study of the anti-GPC3 T-cell engager SAR444200 in patients with advanced solid tumors: Updated efficacy and biomarker analysis.
Bibliographic record
Abstract
2521 Background: SAR444200 is a novel NANOBODY T cell engager that simultaneously binds TCRαβ and glypican-3 (GPC3) to co-engage T cells with GPC3+ tumor cells, resulting in T cell-dependent cellular cytotoxicity. We present updated safety, efficacy, and biomarker data from the dose escalation cohort (Part 1A) of a multicenter, first-in-human, Phase 1/2 trial (NCT05450562). Methods: Patients (Pts) with GPC3+ refractory solid tumors received SAR444200 intravenously (IV) weekly with lead-in doses at dose levels (DLs) 1 (3 mg), 1A (1 mg), 2A (2.5 mg), 3A (4.5 mg), 4A (18 mg), 5A (36 mg), 6A and 7A (different lead-in doses, target dose 70 mg). Pts with ECOG PS ≤1, and ≥1 measurable lesion per RECIST 1.1, were eligible. Primary objective for Part 1A was safety. Key secondary objectives included efficacy and PK/PD. Levels of interleukin-6 (IL-6) and interferon gamma (IFNγ) were evaluated with a multiplex ECL-based assay. Study imaging was performed every 9 weeks following first infusion. Circulating tumor (ct) DNA was analyzed in blood samples using a mutational profiling NGS approach. Results: As of October 15, 2024, 33 pts (23 pts with hepatocellular carcinoma [HCC]) were treated with SAR444200 (premedicated with dexamethasone 15 mg IV or equivalent) for a median of 23 cycles (range, 1–32). Median lines of prior therapies were 3–4. Most pts (32 [97%]) experienced ≥1 AE of any Grade. Grade ≥3 TEAEs in 16 (48.5%) pts and serious TRAEs in 8 (24.2%) pts were reported. 2 Grade 3 cytokine release syndrome events were reported as DLTs at DL6A and 1 at DL7A during the lead-in dosing. Key efficacy data are summarized in Table 1. An increase in IL-6 and IFNγ (maximum of 1326 pg and 461 pg on average per DL, respectively) was observed during lead-in-doses in pts from DL1 to DL5A, supporting CRS diagnosis. Cytokine levels declined after Cycle 1. Of 18 HCC pts with baseline alpha fetoprotein (AFP) ≥20%, 5 (27%) pts showed ≥50% AFP reduction. Median time of observing any AFP decrease was 4 weeks post-treatment. Among these, 3 pts had sustained decrease over 13 cycles. Stable disease (SD) was reported in 10 (30.3%) pts including 2 who were on study drug for 12 and 22 months. Of the 18 pts with measurable ctDNA, 4 (including 3 pts at DL5 and above) had reductions in ctDNA (18%–48%) from baseline. Conclusions: SAR444200 was tolerated at the investigated DLs in pts with GPC3+ advanced solid tumors. Decrease in AFP post treatment along with SD in a subset of pts is suggestive of preliminary anti-tumor activity. Clinical trial information: NCT05450562 . Efficacy analysis. n (%) DL13 mg 2Wn=4 DL1A1 mg 2Wn=4 DL2A2.5 mg 2Wn=4 DL3A4.5 mg 2Wn=4 DL4A18 mg 3Wn=4 DL5A36 mg 3Wn=6 DL6A70 mg 3Wn=3 DL7A70 mg 3Wn = 4 All(N = 33) BORStable DiseaseProgressive disease 1 (25.0)3 (75.0) 1 (25.0)3 (75.0) 1 (25.0)3 (75.0) 1 (25.0)2 (50.0) 2 (50.0)2 (50.0) 3 (50.0)2 (33.3) 1 (33.3)1 (33.3) 02 (50.0) 10 (30.3)18 (54.5) BOR, best overall response; DL, dose level; W, weeks.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.001 |
| Meta-epidemiology (narrow) | 0.002 | 0.001 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.001 | 0.003 |
| Insufficient payload (model declined to judge) | 0.004 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".